Mediterr J Rheumatol 2019;30(3):155-61
Autoantibodies in Myositis. How to Achieve a Comprehensive Strategy for Serological Testing
Authors Information

EUROIMMUN AG, Luebeck, Germany

  1. Bogdanov I, Kazandjieva J, Darlenski R. Dermatomyositis: Current concepts. Clin Dermatol 2018;36:450-8. Epub 2018 Apr 12. [https://doi.org/10.1016/j.clindermatol.2018.04.003] [PMID: 30047429]
  2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7. [https://doi.org/10.1056/NEJM197502202920807] [PMID: 1089199]
  3. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001;357:96-100. [PMID: 11197446]
  4. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995 Jan;6(1):9-13.  [PMID: 7718740]
  5. Chinoy H, Fertig N, Oddis C V, Ollier WER, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9. [https://doi.org/10.1136/ard.2006.068502] [PMID: 17392346] [PMCID: PMC1994304]
  6. Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010;1184:134-53. [https://doi.org/10.1111/j.1749-6632.2009.05119.x] [PMID: 20146695]
  7. Troyanov Y, Targoff IN, Tremblay JL, Goulet JR, Raymond Y, Senecal JL. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore) 2005;84(4):231-49. [https://doi.org/10.1097/01.md.0000173991.74008.b0] [PMID: 16010208]
  8. Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol 2006;24:363-73. [https://doi.org/10.1016/j.clindermatol.2006.07.001] [PMID: 16966018]
  9. Askanas V, Engel WK. Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol 2007 Nov;19(6):550-9. [https://doi.org/10.1097/BOR.0b013e3282efdc7c] [PMID: 17917534]
  10. Bucelli RC, Pestronk A. Immune myopathies with perimysial pathology: Clinical and laboratory features. Neurol Neuroimmunol NeuroInflammation 2018;5(2). [https://doi.org/10.1212/NXI.0000000000000434] [PMID: 29359173] [PMCID: PMC5773856]
  11. Bartoloni E, Gonzalez-Gay MA, Scirè C, Castaneda S, Gerli R, Lopez-Longo FJ, et al. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmun Rev 2017;16(3):253-7. Epub 2017 Jan 29. [https://doi.org/10.1016/j.autrev.2017.01.008] [PMID: 28147261]
  12. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: A comprehensive review. Autoimmun Rev 2014;13(4-5):367-71. Epub 2014 Jan 11. [https://doi.org/10.1016/j.autrev.2014.01.022] [PMID: 24424190] [PMCID: PMC3970575]
  13. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 2016;280(1):8-23. Epub 2015 Nov 25. [https://doi.org/10.1111/joim.12451] [PMID: 26602539]
  14. Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med 2016;374:664-9.
  15. Padala S, Thompson PD. Statins as a possible cause of inflammatory and necrotizing myopathies. Atherosclerosis. 2012 May;222(1):15-21. [https://doi.org/10.1056/NEJMra1515161] [PMID: 26886523]
  16. Werner JL, Christopher-Stine L, Ghazarian SR, Pak KS, Kus JE, Daya NR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 2012;64(12):4087-93. [https://doi.org/10.1002/art.34673] [PMID: 22933019] [PMCID: PMC3510338]
  17. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6(7):620-31. [https://doi.org/10.1016/S1474-4422(07)70171-0] [PMID: 17582362]
  18. Kramp SL, Karayev D, Shen G, Metzger AL, Morris RI, Karayev E, et al. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44 , NT5C1A) in sporadic inclusion body myositis. Autoimmun Highlights 2016;7(16):1-9. [https://doi.org/10.1007/s13317-016-0088-8] [PMID: 27858337] [PMCID: PMC5114199]
  19. Schmidt K, Schmidt J. Inclusion body myositis:  advancements in diagnosis, pathomechanisms, and treatment. Curr Opin Rheumatol 2017;29(6)632-8. [https://doi.org/10.1097/BOR.0000000000000436] [PMID: 28832349]
  20. McGrath ER, Doughty CT, Amato AA. Autoimmune Myopathies: Updates on Evaluation and Treatment. Neurotherapeutics  2018;15(4):976-94. [https://doi.org/10.1007/s13311-018-00676-2] [PMID: 30341597] [PMCID: PMC6277300]
  21. Mastaglia FL, Needham M. Inclusion body myositis: A review of clinical and genetic aspects, diagnostic criteria and therapeutic approaches. J Clin Neurosci 2015;22(1):6-13. [https://doi.org/10.1016/j.jocn.2014.09.012] [PMID: 25510538]
  22. Gunawardena H, Betteridge ZE, McHugh NJ. Newly identified autoantibodies: relationship to idiopathic inflammatory myopathy subsets and pathogenesis. Curr Opin Rheumatol 2008 Nov;20(6):675-80. [https://doi.org/10.1097/BOR.0b013e328313bff4] [PMID: 18946327]
  23. Mariampillai K, Granger B, Amelin D, Guiguet M, Hachulla E, Maurier F, et al. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies. JAMA Neurol 2018;75(12):1528-37. [https://doi.org/10.1001/jamaneurol.2018.2598] [PMID: 30208379] [PMCID: PMC6583199]
  24. Merlo G, Clapasson A, Cozzani E, Sanna L, Pesce G, Bagnasco M, et al. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets. Arch Dermatol Res 2017 Mar;309(2):87-95. [https://doi.org/10.1007/s00403-016-1704-1] [PMID: 27928683]
  25. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006 Jun;8(3):196-203.
  26. Cassius C, Buanec H Le, Bouaziz J, Amode R. Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome. J Immunol Res. 2019;2019. [PMID: 16901077]
  27. Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol 2016;29(5):662-73. [https://doi.org/10.1097/WCO.0000000000000376] [PMID: 27538058]
  28. Montagnese F, Babacic H, Eichhorn P, Schoser B. Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study. J Neurol 2019 Jun;266(6):1358-66. [https://doi.org/10.1007/s00415-019-09266-4] [PMID: 30840145]
  29. Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun  2019;(April):0-1. [https://doi.org/10.1016/j.jaut.2019.04.001] [PMID: 30992170] [PMCID: PMC6580360]
  30. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: Insights into clinical features and outcomes. Arthritis Res Ther 2007;9(4):1-13. [https://doi.org/10.1186/ar2276] [PMID: 17688695] [PMCID: PMC2206383]
  31. Rönnelid J, Barbasso S, Storfors H, Grip K, Rönnblom L, Franck-larsson K, et al. Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies. Autoimmun Rev 2009;9(1):58-61. [https://doi.org/10.1016/j.autrev.2009.03.005] [PMID: 19285154]
  32. Noda S, Asano Y, Tamaki Z, Hirabayashi M, Yamamoto M, Takekoshi T, et al. Dermatomyositis with anti-OJ antibody. Rheumatol Int 2011;31(12):1673-5. [https://doi.org/10.1007/s00296-010-1695-8] [PMID: 21132548]
  33. Vulsteke J-B, Satoh M, Malyavantham K, Bossuyt X, De Langhe E, Mahler M. Anti-OJ autoantibodies: Rare or underdetected? Autoimmun Rev 2019;18(January):658-64. [https://doi.org/10.1016/j.autrev.2019.05.002] [PMID: 31059843]
  34. De Souza FHC, Cruellas MGP, Levy-Neto M, Shinjo SK. [Anti-synthetase syndrome: anti-PL-7, anti-PL-12 and anti-EJ]. Rev Bras Reumatol 2013;53(4):352-7. [https://doi.org/10.1590/S0482-50042013000400007] [PMID: 24217667]
  35. Lazarou IN, Guerne P-A. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 2013 May;40(5):550-64. [https://doi.org/10.3899/jrheum.120682] [PMID: 23504386]
  36. Yang H, Peng Q, Yin L, Li S, Shi J, Zhang Y, et al. Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 2017;19(259). [https://doi.org/10.1186/s13075-017-1469-8] [PMID: 29178913] [PMCID: PMC5702134]
  37. Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): A retrospective study. J Am Acad Dermatol 2011;65(1):25-34. Epub 2011 Apr 29. [https://doi.org/10.1016/j.jaad.2010.09.016] [PMID: 21531040] [PMCID: PMC3167687]
  38. Kobayashi I, Okura Y, Yamada M, Kawamura N, Kuwana M, Ariga T. Anti-melanoma differentiation-associated gene 5 antibody is a diagnostic and predictive marker for interstitial lung diseases associated with juvenile dermatomyositis. J Pediatr 2011;158(4):675-7. Epub 2011 Jan 13. [https://doi.org/10.1016/j.jpeds.2010.11.033] [PMID: 21232756]
  39. Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, et al. Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis. Ann Rheum Dis 2019;78:988-95. [https://doi.org/10.1136/annrheumdis-2018-215004]
  40. Li L, Wang H, Wang Q, Wu C, Liu C, Zhang Y, et al. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease. J Neurol Sci 2019;397(June 2018):123-8. [https://doi.org/10.1016/j.jns.2018.12.040] [PMID: 30616054]
  41. Xie MM, Yan X, Li H, Ding JJ, Gui XH, Liu Y, et al. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases]. Chinese J Tuberc Respir Dis 2018 Aug;41(8):616-21. [https://doi.org/10.3760/cma.j.issn.1001-0939.2018.08.009] [PMID: 30138971]
  42. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, et al. Short-Term and Long-Term Outcome of Anti-Jo1-Positive Patients with Anti-Ro52 Antibody. Semin Arthritis Rheum 2012;41(6):890-9. [https://doi.org/10.1016/j.semarthrit.2011.09.008] [PMID: 22078416]
  43. Herbert MK, Pruijn GJM. Novel serology testing for sporadic inclusion body myositis:  disease-specificity and diagnostic utility. Curr Opin Rheumatol 2015;27(6). [https://doi.org/10.1097/BOR.0000000000000216] [PMID: 26285103]
  44. Cavazzana I, Fredi M, Ceribelli A, Mordenti C, Ferrari F, Carabellese N, et al. Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera. J Immunol Methods 2016;433:1-5. [https://doi.org/10.1016/j.jim.2016.02.017] [PMID: 26906088]
  45. Espinosa-Ortega F, Holmqvist M, Alexanderson H, Storfors H, Mimori T, Lundberg IE, et al. Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2019 Jun;78(6):858-60. [https://doi.org/10.1136/annrheumdis-2018-214690] [PMID: 30760469]
  46. Molberg O, Dobloug C. Epidemiology of sporadic inclusion body myositis. Curr Opin Rheumatol 2016 Nov;28(6):657-60. [https://doi.org/10.1097/BOR.0000000000000327] [PMID: 27541181]
  47. Pluk H, van Hoeve BJA, van Dooren SHJ, Stammen-Vogelzangs J, van der Heijden A, Schelhaas HJ, et al. Autoantibodies to cytosolic 5′-nucleotidase 1A in inclusion body myositis. Ann Neurol  2013 Mar 1;73(3):397-407. [https://doi.org/10.1002/ana.23822] [PMID: 23460448]
  48. Larman BH, Salajegheh M, Nazareno R, Lam T, Sauld J, Steen H, et al. Cytosolic 5′-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol 2013 Mar 1;73(3):408-18. [https://doi.org/10.1002/ana.23840] [PMID: 23596012]
  49. Rietveld A, van den Hoogen LL, Bizzaro N, Blokland SLM, Dähnrich C, Gottenberg JE, et al. Autoantibodies to cytosolic 5’-nucleotidase 1A in primary Sjögren’s syndrome and systemic lupus erythematosus. Front Immunol 2018;9(Jun):1-6. [https://doi.org/10.3389/fimmu.2018.01200] [PMID: 29922285] [PMCID: PMC5996144]
  50. Herbert MK, Stammen-Vogelzangs J, Verbeek MM, Rietveld A, Lundberg IE, Chinoy H, et al. Disease specificity of autoantibodies to cytosolic 5’-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Ann Rheum Dis 2016 Apr;75(4):696-701. [https://doi.org/10.1136/annrheumdis-2014-206691] [PMID: 25714931] [PMCID: PMC4699257]
  51. Lloyd TE, Christopher-Stine L, Pinal-Fernandez I, Tiniakou E, Petri M, Baer A, et al. Cytosolic 5’-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care Res (Hoboken) 2016 Jan;68(1):66-71. [https://doi.org/10.1002/acr.22600] [PMID: 25892010] [PMCID: PMC4887848]